Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metagenomi, Inc. - Common Stock (NQ:MGX)

3.400 +0.270 (+8.63%)
Streaming Delayed Price Updated: 3:18 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Metagenomi, Inc. - Common Stock

Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected
Metagenomi Inc (NASDAQ:MGX) reported Q2 2025 earnings with revenue beating estimates at $8.51M and a narrower loss of -$0.54 per share. Shares dipped slightly amid investor caution over cash burn and... 
Via Chartmill
Which stocks are gapping on Wednesday?
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' Jibe
OpenAI CEO Sam Altman regrets underestimating Elon Musk's potential abuse of power to block OpenAI's $500B Stargate deal. Tensions also rise with Microsoft. 
Via Benzinga
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
Expert Outlook: Metagenomi Through The Eyes Of 4 Analysts
 
Via Benzinga
Peeling Back The Layers: Exploring Metagenomi Through Analyst Insights
 
Via Benzinga
Unveiling 4 Analyst Insights On Metagenomi
 
Via Benzinga
Demystifying Metagenomi: Insights From 4 Analyst Reviews
 
Via Benzinga
Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week
Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025. 
Via Stocktwits
Stargate, Netflix, GE Aerospace, Twilio, and More
There's a lot for investors to talk about. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Cogent Communications To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
MGX Stock Earnings: Metagenomi Beats EPS, Beats Revenue for Q2 2024
MGX stock results show that Metagenomi beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024
MGX stock results show that Metagenomi missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet
A bumpy start can't detract from this company's strong balance sheet. 
Via The Motley Fool
Topics Initial Public Offering
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a... 
Via Talk Markets
Topics Initial Public Offering
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.